Skip to content

Educational content only. Not investment advice: no price targets or buy and sell recommendations of our own.

Companies / Vertex Pharmaceuticals

VRTX

Vertex Pharmaceuticals

16 active clinical studies registered on ClinicalTrials.gov, the most advanced in Phase 4. Next estimated primary completion: 9 Jun 2027.

Clinical pipeline

Primary completionPhaseStatusCondition and study
9 Jun 2027 Phase 3? Recruiting Beta-Thalassemia, Thalassemia, Hematologic Diseases
Evaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease · NCT05477563
22 Jul 2027 Phase 2? Active, not recruiting Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Phase 2a Study of VX-407 in Participants With ADPKD Who Have a Subset of PKD1 Gene Variants (AGLOW) · NCT07161037
30 Sep 2027 Phase 3? Active, not recruiting Cystic Fibrosis
Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis Participants 12 Months of Age and Older · NCT06460506
1 Oct 2027 Phase 4? Not yet recruiting Ankle Osteoarthritis, Postoperative Pain, Acute Pain
Suzetrigine for Postoperative Pain After Total Ankle Replacement · NCT07795827
28 Dec 2027 Phase 4? Enrolling by invitation Pain, Acute Postoperative, Breast Disease
Suzetrigine for Non-Mastectomy Breast Surgery · NCT07463430
31 Dec 2027 Phase 3? Recruiting Diabetes Mellitus, Type 1, Impaired Hypoglycemic Awareness, Severe Hypoglycemia
A Safety, Tolerability, and Efficacy Study of VX-880 in Participants With Type 1 Diabetes · NCT04786262
Jan 2028 Phase 4? Not yet recruiting Postoperative Pain
Suzetrigine Added to Multimodal Analgesia for Women Undergoing Minimally Invasive Hysterectomy · NCT07836010
2 Jun 2028 Phase 2/3? Recruiting Proteinuric Kidney Disease
Phase 2/3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1-Mediated Proteinuric Kidney Disease · NCT05312879
Aug 2028 Phase 4? Not yet recruiting Knee Arthritis, Knee Osteoarthritis
Role of Suzetrigine as a Part of a Multimodal Regimen to Reduce Pain and Opioid Use After Total Knee Arthroplasty · NCT07624526
29 Dec 2028 Phase 2/3? Recruiting Primary Membranous Nephropathy
Evaluation of Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN) · NCT07204275
30 Jan 2029 Phase 2? Enrolling by invitation Myotonic Dystrophy Type 1 (DM1)
A Study of Long-term Safety and Efficacy of VX-670 in Participants With Myotonic Dystrophy Type I · NCT06926621
2 Mar 2029 Phase 2? Recruiting Myasthenia Gravis, Generalized
A Phase 2 Study to Evaluate Povetacicept in Adults With Generalized Myasthenia Gravis · NCT07501702
30 Jul 2029 Phase 3? Enrolling by invitation Cystic Fibrosis
Evaluation of Long-Term Safety and Efficacy of Vanzacaftor/Tezacaftor/Deutivacaftor in Cystic Fibrosis Participants 1 Year of Age and Older · NCT05844449
28 Dec 2029 Phase 3? Enrolling by invitation Immunoglobulin A Nephropathy
A Phase 3 Open-Label Study of Long-term Treatment With Povetacicept in Adults With Immunoglobulin A Nephropathy · NCT07807995
30 Jun 2030 Phase 3? Active, not recruiting Cystic Fibrosis
Evaluation of VX-121/Tezacaftor/Deutivacaftor in Cystic Fibrosis (CF) Participants 1 Through 11 Years of Age · NCT05422222
Dec 2032 N/A Recruiting DM1, Myotonic Dystrophy, Myotonic Dystrophy 1
Establishing Biomarkers and Clinical Endpoints in Myotonic Dystrophy Type 1 (END-DM1) Extension · NCT07700225

Source: ClinicalTrials.gov, studies with the company as sponsor and an active status. Data fetched 7 October 2026.

Recent news

Headlines from other publications, linked to the original. We do not rewrite or summarise them. Analyst ratings and price targets are the opinion of the cited source, not ours.